You are here

Our science / Clinical Trials / Find a Trial / NCT01227395

Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients

Back to Search Print Save as PDF Bookmark Trial

NCT01227395

Last updated on April 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
HIV Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0+
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Patients need to be administered Zithromac Tablets 600mg in order to be enrolled in the
surveillance.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Patients not administered Zithromac Tablets 600mg.

NCT01227395
Pfizer
Completed
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Pneumococcal Infections
A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age
NCT03313050
All Genders
50+
Years
Multiple Sites
Clostridium Difficile Infection
Clostridium Difficile Vaccine Efficacy Trial
NCT03090191
All Genders
50+
Years
Multiple Sites
Meningococcal Infections
Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination
NCT01934140
All Genders
17+
Years
Multiple Sites
Meningococcal Infections
Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children
NCT01900899
All Genders
0+
Years
Multiple Sites
Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Drug Use Investigation On Zithromac Tablets 600mg In HIV Patients (Post Marketing Commitment Plan)
The investigation will be conducted for the purpose of determining the condition of occurrence of Adverse Events under the actual post-marketing use of Zithromac 600mg Tablet, verifying the therapeutic effects, detecting unknown Adverse Drug Reactions and drug interactions and determining the factors affecting safety and efficacy.
All the patients whom an investigator prescribes the first Zithromac Tablets 600mg should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Probability Sample
The subjects whom an investigator involving A0661097 prescribes the Azithromycin Tablets 600mg (Zithromac Tablets 600mg).
HIV Infection
Drug: Azithromycin

Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.

Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults.

Other Name: Zithromac, Zithromax, Azithromycin
Azithromycin
Patients taking Azithromycin.
Intervention: Drug: Azithromycin
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
476
March 2012
March 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patients need to be administered Zithromac Tablets 600mg in order to be enrolled in the surveillance.

Exclusion Criteria:

Patients not administered Zithromac Tablets 600mg.
Sexes Eligible for Study: All
Child, Adult, Senior
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01227395
A0661097
No
Not Provided
Not Provided
Pfizer
Pfizer
Altmarc Inc.
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
April 2013

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now